<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367917">
  <stage>Registered</stage>
  <submitdate>6/02/2015</submitdate>
  <approvaldate>27/02/2015</approvaldate>
  <actrnumber>ACTRN12615000193572</actrnumber>
  <trial_identification>
    <studytitle>Blood test for diagnosis of cancer cachexia</studytitle>
    <scientifictitle>Comparison of Il-6 and CRP levels in patients with non-small cell lung cancer, small cell lung cancer, ovarian cancer, colon cancer, cervical cancer, or endometrial cancer with or without cancer cachexia.</scientifictitle>
    <utrn>U1111-1166-7826</utrn>
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cancer Cachexia</healthcondition>
    <healthcondition>Cancer , Lung-Non small cell</healthcondition>
    <healthcondition>Cancer, Lung-small cell</healthcondition>
    <healthcondition>Cancer, Ovarian and primary peritoneal</healthcondition>
    <healthcondition>Cancer, Womb(Uterine or endometrial cancer)</healthcondition>
    <healthcondition>Cancer, Bowel-Back passage(rectum) or large bowel (colon).</healthcondition>
    <healthcondition>Cancer, Cervical (cervix).</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>We will take blood samples from both the cases and controls during their check-up. We will use ELISA Kits to measure IL-6 and CRP in each case and controls. Then we will get the results from both the cases and controls and compare it. The blood sample will be taken once only.</interventions>
    <comparator>Control group will be patients with the same type of cancer but do not have cachexia.</comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The 1st primary outcome of the study is to compare the level of IL-6  in patients with cancer cachexia and patients with the same cancer type that do not have cachexia . The outcome will be assed by serum analysis using ELISA (test).</outcome>
      <timepoint>We aim to detect a minimum of 3 mmol/ L between the cases and the controls at one month after the recruitment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The 2nd primary outcome is to compare the level of CRP in the cases  with the level of CRP in the controls by serum analysis using ELISA (test).</outcome>
      <timepoint>At one month after the recruitment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine if IL-6 can be used as a predictive biomarker for the likely onset of cancer cachexia by analysis of the serum using ELISA (test).</outcome>
      <timepoint>At 3 months after the result of the analysis.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine if CRP can be used as a predictive biomarker for the likely onset of cancer cachexia by analysis of serum using ELISA (test).</outcome>
      <timepoint>At 3 months after the analysis.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients ( cases) from Cachexia clinic at the National Cancer Institute, Cairo University Egypt who have non small cell lung cancer, small cell lung cancer, colon cancer, cervical cancer, ovarian cancer or endometrial cancer that are diagnosed with cancer cachexia. Controls, patients from the oncology clinic who have the same type of cancer but do not have cachexia. The primary diagnosis for the controls should be less than 6 months. All the patients should have a biopsy proven the diagnosis of cancer. None of the patients will have an inflammatory diseases other than cancer or cancer cachexia.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>The primary diagnosis for the controls more than 6 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>2/02/2015</anticipatedstartdate>
    <actualstartdate>2/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate>22/12/2016</actualenddate>
    <samplesize>321</samplesize>
    <actualsamplesize>357</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>8/01/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Cairo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>School of Medicine, Faculty of Health, Deakin University</primarysponsorname>
    <primarysponsoraddress>75 Pigdons Road, Waurn Pond Campus Geelong, VIC 3216, Australia.</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>School Of Medicine, Faculty of Health, Deakin University</fundingname>
      <fundingaddress>75 Pigdons Road, Waurn Pond Campus Geelong, VIC 3216, Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>National Cancer Institute, Cairo University, Egypt</sponsorname>
      <sponsoraddress>Cairo, Fom  El Kl Khalig, Cairo 11796, Egypt.</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Case Control study, with two controls (n=214) per cachexia patient (n=107), will be done in collaboration between the School of Medicine, Deakin University and National Cancer Institute, Cairo University Egypt. The primary aim is to compare the level of IL-6 and CRP in patients with cancer cachexia and patients without cachexia. The secondary aim will be to determine if IL-6 and or CRP can be used as a predictive biomarker for the likely onset of cachexia.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional Review Board Decision</ethicname>
      <ethicaddress>National Cancer Institute, Cairo University, Egypt</ethicaddress>
      <ethicapprovaldate>19/01/2016</ethicapprovaldate>
      <hrec>201516010.7</hrec>
      <ethicsubmitdate>8/12/2015</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>National cancer institute</ethicname>
      <ethicaddress>National Cancer institute, Cairo University , Egypt, Fom El Khalig, Cairo 11796, Egypt</ethicaddress>
      <ethicapprovaldate>25/11/2014</ethicapprovaldate>
      <hrec>FWA No FWA00007284, IRB No IRB00004025, MD2010014011.3</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name> Jagat Kanwar</name>
      <address>75 Pigdons Road, Waurn Pond, VIC 3216, School of Medicine, Deakin University Australia</address>
      <phone>+61433737256</phone>
      <fax />
      <email>jagat.kanwar@deakin.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ayman Aboda</name>
      <address>1 Roslyn Road, Belmont VIC 3216, Australia.

Other address: 75 Pigdons Road, Waurn Pond, VIC 3216, School of Medicine, Deakin University, Australia</address>
      <phone>+61404953667</phone>
      <fax />
      <email>ayman.aboda@deakin.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Jagat Kanwar</name>
      <address>75 Pigdons Road, Waurn Pond, VIC 3216, Deakin University, School of Medicine, Australia</address>
      <phone>+61433737256</phone>
      <fax />
      <email>jagat.kanwar@deakin.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ayman Aboda</name>
      <address>1 Roslyn Road, Belmont, VIC 3216

Other address:
 75 Pigdons Road, Waurn Pond, VIC 3216, School of Medicine, Deakin University, Australia</address>
      <phone>+61404953667</phone>
      <fax />
      <email>ayman.aboda@deakin.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>